002589.SZ
瑞康医药
SZSE · Healthcare · F 批发零售 · CN
CNY 3.02
−5.03%Year over year
Reported trailing growth
- Revenue
- -5.9%
- EBITDA
- —
- EBIT
- +39.0%
- EPS
- +211.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +535.4%
- EBITDA
- +893.8%
- EPS
- +9536.3%
Three-year CAGR
- Revenue
- -16.0%
- EBITDA
- +35.7%
- EBIT
- +15.4%
- Net income
- -11.1%
- EPS
- -13.9%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026